Ind Swift Laboratories Share Price

Ind Swift Laboratories Share Price

NSE: INDSWFTLAB
|
Pharmaceuticals

₹ 361.35

+₹0.30 (0.08%)
1D
Last updated 13 Oct, 2026, 15:50 IST

Ind Swift Laboratories Share Price Today

As of 13 Oct 2026, Ind Swift Laboratories share price is ₹361.35. The stock opened at ₹363.50, compared to its previous close of ₹361.05. During today's trading session, Ind Swift Laboratories share price moved in the range of ₹345.00 to ₹367.25, with an average price of ₹356.13 for the day. Looking at its last 52-week, the stock has touched a low of ₹87.15 and a high of ₹424.75. On the performance front, Ind Swift Laboratories share price has increased by 159.68% over the last six months and is up 235.55% on a year-on-year basis.

₹345.00
0.08% up today
₹367.25
1D LOW
1D HIGH

Ind Swift Laboratories Returns Calculator

Volume
3,65,436
Average traded price
₹354.67
Last traded time
03:50:04 13 Oct
Last traded quantity
3
Circuit
L
H
₹288.85
₹433.25
52-week
L
H
₹87.15
₹424.75
Mkt Cap Cr
3,139.31
P/E
54.78
P/B
2.27
ROA
3.42%
ROE
3.57%
ROCE
4.36%
Quick Ratio
3.22
EV/EBITDA
26.28
Based on fundamentals, this stock's
Step 1 of 5
Performance
Very Poor
Ind-Swift Labs. has not beaten FD return of 7%
Step 1 of 5
Valuation
Overvalued
Ind-Swift Labs. appears overvalued compared to its peers
Step 4 of 5
Earnings
Good
Ind-Swift Labs. revenue, operating profit and net profit are growing
Peer Comparison
Peer comparison — key ratios
NameMkt Cap CrP/EP/BROAROEROCEQuick RatioEV/EBITDA
Sun Pharmaceutical Industries4,22,067.0134.835.0511.19%13.74%17.33%2.3121.42
Divis Laboratories2,48,982.9885.1214.8514.6%15.32%19.56%3.556.28
Torrent Pharmaceuticals1,77,251.4282.5521.164.87%25.49%13.85%0.7538.11
Zydus Lifesciences1,13,615.6924.744.198.57%18.59%17.35%0.9114.87
Laurus Labs1,11,898.66102.6321.1110.38%16.77%16.14%0.6853.86
Cipla1,06,129.9631.623.087.92%11.27%14.95%2.517.83
Dr. Reddy's Laboratories1,02,707.4132.262.75.48%11.07%12.54%1.3515.86
Mankind Pharma99,089.5247.926.087.36%11.74%13.13%0.7425.7
Aurobindo Pharma97,972.4726.42.596.34%9.25%11.76%1.1512.47
Lupin89,628.8316.033.9614.47%23.76%24.88%1.429.56

Auto-generated based on historical fundamentals; not a recommendation to buy/sell.

About Ind Swift Laboratories

Ind Swift Laboratories Share Price
ISIN
INE915B01019
Sector Market Cap
₹ 3,139.31 Cr

Ind-Swift Laboratories Limited is an India-based company, which is engaged in the business of manufacturing active pharmaceutical ingredients (APIs), intermediates and formulations. The Company operates in the Pharmaceutical Business segment. It also focuses on manufacturing formulations. The Company’s products include APIs and Impurities. Its APIs therapeutic category includes Macrolide Antibiotic, Cardiovascular, Antihistaminic, Antidiabetic, Antipsyhotic, Bone Resorption Inhibitor, and Aromatase Inhibitor. Its products include Clarithromycin, Clarithromycin Coated Granules, Clarithromycin Citrate, Atorvastatin Calcium Crystalline, Atorvastatin Calcium Amorphous, Clopidogrel HCl, Ezetimibe, Ivabradine Oxalate, Ranolazine, Aripiprazole, Risedronate Sodium, Ropinirole HCl, Cinacalcet HCl, Letrozole, and Anastrozole. Its products under development include Sitagliptin Phosphate, Mirabegron, Bempedoic Acid, Lasmiditan, and Eltrombopag Olamine.

Ind Swift Laboratories Financial Highlights

  • Revenue: Ind Swift Laboratories reported revenue of ₹688.26 crore in FY26 vs ₹643.09 crore in FY25. It showed an increase of 7.02% on a yearly basis.
  • Operating Profit: Ind Swift Laboratories reported an operating profit of ₹49.05 crore in FY26 vs ₹257.80 crore in FY25. It showed a decrease of 80.97% on a year-on-year basis.
  • Net Profit: Ind Swift Laboratories reported a net profit of ₹41.32 crore in FY26 vs ₹250.53 crore in FY25. It showed a decrease of 83.51% on a yearly basis.

Ind Swift Laboratories Quarterly Result Highlights

  • Ind Swift Laboratories reported revenue of ₹199.10 crore in Jun 2026, compared with ₹172.01 crore in Mar 2026, representing an increase of 15.75% on a quarter-on-quarter (QoQ) basis.
  • Ind Swift Laboratories reported an operating profit of ₹32.56 crore in Jun 2026, compared with ₹11.96 crore in Mar 2026, representing an increase of 172.24% on a quarter-on-quarter (QoQ) basis.
  • Ind Swift Laboratories reported a profit of ₹24.57 crore in Jun 2026, compared with ₹15.11 crore in Mar 2026, reflecting an increase of 62.61% on a QoQ basis.
  • The earnings per share (EPS) of Ind Swift Laboratories stood at ₹5.16 during Jun 2026.

Data Source: BSE, Company announcements

Securities shown are illustrative, not recommendations. Past performance does not guarantee future results.

Know more
Promoters
42.93%
FII
10.90%
Other DII
0.15%
Retail and other
46.01%
Mutual funds
0.00%
Foreign Institutional Investor (FII)
FII shareholding by period
Feb 202613.80%
Mar 202613.88%
Jun 202610.70%
Sep 202610.90%
1 day
+0.08%
1 week
-9.76%
1 month
-6.23%
1 year
+235.55%
3 years
+288.55%
5 years
+474.48%
Day
Open / Close
Change %
12 Oct 26
₹362.25 / ₹361.05
+0.04%
09 Oct 26
₹367.00 / ₹360.90
-1.42%
08 Oct 26
₹391.50 / ₹366.10
-6.39%
07 Oct 26
₹403.40 / ₹391.10
-2.33%
Show more

Ind Swift Laboratories Financials

Full statement

Income Statement · Consolidated

Income Statement · Consolidated — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Revenue₹649.14₹574.24₹1,280.90₹1,207.31
Other Income₹46.97₹68.86₹45.37₹33.50
Total Revenue₹696.10₹643.09₹1,326.27₹1,240.81
Total Expenses₹634.34₹608.50₹1,131.10₹1,127.64
Profit Before Tax₹50.76₹257.80₹581.76₹86.52
Tax₹7.73₹7.27₹160.31₹38.69
Profit After Tax₹43.03₹250.53₹421.45₹47.83
EPS - Basic₹5.16₹37.24₹71.24₹8.10
EPS - Diluted₹5.03₹35.21₹71.24₹8.10

Cash Flow · Consolidated

Cash Flow · Consolidated — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Profit before tax₹61.76₹34.59₹195.17₹113.17
Income before WC changes₹41.90-₹2.37₹319.93₹245.95
Change in Assets-₹150.07₹47.29-₹515.89-₹68.39
Change in Liabilities₹46.70-₹67.05₹32.84₹17.07
Change in WC-₹103.37-₹19.76-₹483.05-₹51.33
Cash flow from Operations-₹68.17-₹28.69-₹163.12₹194.62
Cash flow from Investing-₹72.68-₹113.13-₹104.32-₹13.37
Cash flow from Financing₹141.81₹72.42₹698.91-₹185.66
Total Cash Flow₹0.96-₹69.39₹431.48-₹4.41
Cash (Start of the year)₹425.11₹493.93₹18.20₹21.48
Cash (End of the year)₹429.85₹425.11₹449.68₹17.07

Balance Sheet · Consolidated

Balance Sheet · Consolidated — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Non-Current Assets₹696.60₹572.99₹503.98₹659.55
Current Assets₹976.75₹865.35₹661.13₹1,164.52
Total Assets₹1,673.35₹1,438.34₹1,165.11₹1,824.06
Current Liabilities₹257.29₹220.58₹221.28₹371.09
Net Current Asset₹719.47₹644.77₹439.85₹793.43
Non-Current Liabilities₹32.10₹44.79₹12.39₹771.04
Equity Capital₹1,383.97₹1,172.97₹931.44₹681.93
Total Equity & Liabilities₹1,673.35₹1,438.34₹1,165.11₹1,824.06

Income Statement · Standalone

Income Statement · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Revenue₹635.89₹562.17₹1,672.57₹1,151.96
Other Income₹46.96₹68.75₹88.30₹33.28
Total Revenue₹682.84₹630.92₹1,760.86₹1,185.24
Total Expenses₹621.62₹589.98₹1,557.92₹1,079.39
Profit Before Tax₹50.22₹264.14₹593.93₹79.20
Tax₹7.66₹8.06₹57.76₹36.73
Profit After Tax₹42.56₹256.09₹536.18₹42.47
EPS - Basic₹5.09₹38.07₹90.74₹7.19
EPS - Diluted₹4.97₹36.00₹90.74₹7.19

Cash Flow · Standalone

Cash Flow · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Profit before tax₹61.22₹40.94₹202.94₹105.85
Income before WC changes₹41.29₹4.02₹378.03₹238.62
Change in Assets-₹119.63-₹7.82-₹526.27-₹73.90
Change in Liabilities₹44.85-₹34.93-₹17.50₹17.95
Change in WC-₹74.79-₹42.75-₹543.77-₹55.95
Cash flow from Operations-₹40.19-₹45.30-₹165.74₹182.67
Cash flow from Investing-₹100.16-₹109.67-₹27.71-₹13.69
Cash flow from Financing₹145.26₹77.44₹657.78-₹168.41
Total Cash Flow₹4.90-₹77.53₹464.33₹0.58
Cash (Start of the year)₹410.09₹487.62₹23.28₹9.38
Cash (End of the year)₹414.99₹410.09₹487.62₹9.96

Balance Sheet · Standalone

Balance Sheet · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Non-Current Assets₹779.43₹628.32₹556.24₹714.20
Current Assets₹874.91₹793.73₹852.16₹1,074.07
Total Assets₹1,654.34₹1,422.05₹1,408.40₹1,788.27
Current Liabilities₹251.55₹216.35₹397.71₹350.05
Net Current Asset₹623.36₹577.38₹454.46₹724.02
Non-Current Liabilities₹32.10₹41.63₹212.55₹762.88
Equity Capital₹1,370.70₹1,164.08₹798.15₹675.35
Total Equity & Liabilities₹1,654.34₹1,422.05₹1,408.40₹1,788.27
* All values are in INR Crore
Qty
Bid
0
0
0
0
0
0
0
0
0
0
Ask
Qty
361.35
492
0
0
0
0
0
0
0
0
Bid Total: 0
Ask Total: 492
Buy orders: 0%
Sell orders: 100%
Bearish
2
Neutral
3
Bullish
3
Slightly Bullish
by SEBI experts
Expert Pick
EXPPICK
Stop-loss
Entry price
Target
Indicator
Value
Verdict
RSI (14)
45.01
Neutral
ATR (14)
24.54
Neutral
STOCH(9,6)
14.78
Bullish
STOCH RSI (14)
0.24
Bullish
ADX(9)
25.85
Bearish
UO(9)
38.28
Neutral
ROC(12)
-10.86
Bearish
WillR(14)
-85.22
Bullish
Period
Simple value
Exponential vaue
5D
375.92
371.68
10D
387.04
379.86
20D
387.28
379.68
50D
345.47
345.04
100D
268.65
290.93
Volume trend — traded volume by day
13 Oct3L
12 Oct3L
9 Oct6L
8 Oct8L
7 Oct2L
6 Oct3L
Average4L

Technical indicators used here are for indicative purposes only. Kindly do not treat it as an investment or trading advice

Compare against other stocks
Ind Swift Laboratories Share Price
Ind Swift Laboratories
Pharmaceuticals
Add Stock
Add Another

Ind Swift Laboratories Share Price FAQs

Disclaimer: The information on this page, including prices, charts, financials, ratios, and other data, is provided for informational and educational purposes only. It is not investment advice, a research report, or a recommendation or solicitation to buy, sell, or hold any security. Data is sourced from third parties and exchanges, may be delayed, and is not guaranteed to be accurate, complete, or timely. Upstox is not liable for any loss arising from its use.